---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009854"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T12:40:06.228272+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma raises $5.45M via convertible preferred stock and warrants with greenshoe option up to $19.8M

## Summary
- Private placement of up to 6,056 shares of Series L 10% Convertible Preferred Stock at $1,000 stated value; net proceeds $5.45M.
- Conversion price $2.043 per share; warrants exercisable at same price for five years; full ratchet anti-dilution with floor of $0.454.
- Dividends at 10% annual rate until May 2026, increasing to 12% thereafter; payable quarterly in cash or common stock.
- Company to seek shareholder approval for issuance over 19.99% of outstanding common stock; officers/directors locked up.
- Registration rights agreement requires filing within 30 days; liquidated damages of 1.5% per month if not effective within 90 days.

## SEC filing metadata
- accession: 0001641172-25-009854
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/0001641172-25-009854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009854
- JSON: https://secwatch.observer/filing/0001641172-25-009854.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009854.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.